**SECURITIES
      AND EXCHANGE COMMISSION**


**Washington,
      D.C. 20549**





**FORM
      10-Q**




xQUARTERLY
      REPORT
      PURSUANT TO SECTION 13 OR 15(d) OF
      THE
      SECURITIES EXCHANGE ACT OF 1934





For
      the
      quarterly period ended March
      31, 2007





oTRANSITION
      REPORT
      PURSUANT TO SECTION 13 OR 15(d) OF
      THE
      SECURITIES EXCHANGE ACT OF 1934





For
      the
      transition period from _____________ to _____________





Commission
      File Number 0-28674





CADUS
      CORPORATION


(Exact
      Name of Registrant as Specified on its Charter)





Delaware
            
            13-3660391(State
                of Other Jurisdiction of Incorporation or Organization)
            
            (I.R.S.
                Employer Identification No.)767
                Fifth Avenue, New York, New York
            
            10153(Address
                of Principal Executive Offices)
            
            (Zip
                Code)Registrant’s
                Telephone Number, Including Area Code
            
            (212)
                702-4315




Indicate
      by check mark whether the registrant (1) has filed all reports required to
      be
      filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during
      the
      preceding 12 months (or for such shorter period that the registrant was required
      to file such reports), and (2) has been subject to such filing requirements
      for
      the past 90 days.




Yes
x No
o





Indicate
      by check mark whether the registrant is a large accelerated filer, an
      accelerated filer, or a non-accelerated filer. See definition of “accelerated
      filer and large accelerated filer in Rule 12-b-2 of the Exchange Act.





Large
      Accelerated Filer o   Accelerated
      Filer o   Non-Accelerated
      Filer x





Indicate
      by check mark whether the registrant is a shell company (as defined in Rule
      12-b-2 of the Exchange Act).




Yes
o No
x




The
      number of shares of registrant’s common stock, $0.01 par value, outstanding as
      of April 30, 2007 was 13,144,040.







**CADUS
      CORPORATION**





**INDEX**


Page
                No.SPECIAL
                NOTE REGARDING FORWARD LOOKING STATEMENTS
            3PART
                I - CONDENSED CONSOLIDATED FINANCIAL INFORMATIONItem
                1.Condensed
                Consolidated Financial StatementsCondensed
                Consolidated Balance Sheets - March 31, 2007 (unaudited) and December
                31,
                2006 (audited)
            4Condensed
                Consolidated Statements of Operations - Three Months Ended March
                31, 2007
                and 2006 (unaudited)
            5Condensed
                Consolidated Statements of Cash Flows - Three Months Ended March
                31, 2007
                and 2006 (unaudited)
            6Notes
                to Condensed Consolidated Financial Statements (unaudited)
            7 -
                9Item
                2.Management’s
                Discussion and Analysis of Financial Condition and Results of
                Operations
            10 -
                11Item
                3.Quantitative
                and Qualitative Disclosures About Market Risk
            11Item
                4.Controls
                and Procedures
            11PART
                II - OTHER INFORMATIONItem
                1.Legal
                Proceedings
            11Item
                1A. Risk Factors
            11
                - 12Item
                2.Unregistered
                Sales of Equity Securities and Use of Proceeds
            12Item
                3.Defaults
                Upon Senior Securities
            12Item
                4.Submission
                of Matters to a Vote of Security Holders
            12Item
                5.Other
                Information
            12Item
                6.Exhibits
            12SIGNATURES
            13EXHIBIT
                INDEX
            14





2





**SPECIAL
      NOTE REGARDING FORWARD LOOKING STATEMENTS**





Certain
      statements in this Quarterly Report on Form 10-Q constitute “forward-looking
      statements” within the meaning of Section 27A of the Securities Act of 1933 and
      Section 21E of the Securities Exchange Act of 1934, as amended. All statements
      other than statements of historical fact are “forward-looking statements” for
      purposes of federal and state securities laws, including any projections or
      expectations of earnings, revenue, financial performance, liquidity and capital
      resources or other financial items; any statement of our plans, strategies
      and
      objectives for our future operations; any statements regarding future economic
      conditions or performance; any statements of belief; and any statements of
      assumption underlying any of the foregoing. Forward-looking statements may
      include the words “may,” “will,” “should,” “could,” “would,” “predicts,”
“potential,” “continue,” “expects,” “anticipates,” “future,” “intends,” “plans,”
“believes,” “estimates” and other similar words. Although the Company believes
      that the expectations reflected in our forward-looking statements are
      reasonable, such forward-looking statements involve known and unknown risks,
      uncertainties, and other factors which may cause the actual results,
      performance, or achievements of the Company to be materially different from
      any
      future results, performance or achievements expressed or implied by such
      forward-looking statements. Factors that could cause or contribute to such
      differences include, but are not limited to, risks and uncertainties relating
      to
      the Company's ability to license its technologies to third parties, the
      Company's inability to acquire and operate other companies, the Company's
      capital needs and uncertainty of future funding, the Company's history of
      operating losses, the unpredictability of patent protection, risk of
      obsolescence of the Company's technologies, as well as other risks and
      uncertainties discussed in the Company’s annual report on Form 10-K for the year
      ended December 31, 2006. The forward-looking statements made in this Quarterly
      Report on Form 10-Q are made only as of the date hereof and the Company does
      not
      have or undertake any obligation to publicly update any forward-looking
      statements to reflect subsequent events or circumstances unless otherwise
      required by law.




3




ITEM
      1.  CONDENSED
      CONSOLIDATED FINANCIAL STATEMENTS





**CADUS
      CORPORATION**


**Condensed
      Consolidated Balance Sheets**





March
                31,
              2007
            
            December
                31, 2006(Unaudited)
            
            (Audited)**ASSETS**Current
                assets:Cash
                and cash equivalents
            
            $
            24,800,051
            
            $
            24,602,202Prepaid
                and other current assets
            
            
            21,410
            
            
            5,210Investment
                in marketable securities
            
            
            468,132
            
            
            628,585Total
                current assets
            
            
            25,289,593
            
            
            25,235,997Investment
                in other ventures
            
            
            176,648
            
            
            173,427Patents,
                net
            
            
            615,659
            
            
            637,267Total
                assets
            
            $
            26,081,900
            
            $
            26,046,691**LIABILITIES
                AND STOCKHOLDERS’ EQUITY**Current
                liabilities:Accrued
                expenses and other current liabilities
            
            $
            147,192
            
            $
            61,307Total
                current liabilities
            
            
            147,192
            
            
            61,307CommitmentsStockholders’
                equity:Common
                stock
            
            
            132,857
            
            
            132,857Additional
                paid-in capital
            
            
            59,844,355
            
            
            59,844,355Accumulated
                deficit
            
            
            (33,742,429
            )
            
            (33,183,960
            )Accumulated
                other comprehensive (loss) income
            
            
            —
            
            
            (507,793
            )Treasury
                stock
            
            
            (
                300,075
            )
            
            (
                300,075
            )Total
                stockholders’ equity
            
            
            25,934,708
            
            
            25,985,384Total
                liabilities and stockholder’s equity
            
            $
            26,081,900
            
            $
            26,046,691




See
      accompanying notes to condensed consolidated financial statements.




4





**CADUS
      CORPORATION**


**Condensed
      Consolidated Statements of Operations**





Three
                Months Ended
              March
                31,2007
            
            2006(Unaudited)
            
            (Unaudited)License
                and maintenance fees
            
            $
            100,000
            
            $
            100,000Total
                revenues
            
            
            100,000
            
            
            100,000Costs
                and expenses:General
                and administrative expenses
            
            
            314,091
            
            
            261,202(Gain)
                from equity in other ventures
            
            
            (
                3,221
            )
            
            (
                2,369
            )Total
                costs and expenses
            
            
            310,870
            
            
            258,833Operating
                loss
            
            
            (210,870
            )
            
            (158,833
            )Other
                income:Interest
                income
            
            
            320,647
            
            
            259,644Loss
                on write down of marketable securities
            
            
            (668,246
            )
            
            -(Loss)
                income before income taxes
            
            
            (558,469
            )
            
            100,811Income
                taxes
            
            
            -
            
            
            -Net
                (loss) income
            
            
            (558,469
            )
            
            100,811Basic
                and diluted net (loss) income per weighted average share of common
                stock
                outstanding
            
            
            ($
                0.04
            )
            $
            0.01Weighted
                average shares of common stock outstanding - basic and
                diluted
            
            
            13,144,040
            
            
            13,144,040




See
      accompanying notes to condensed consolidated financial statements.




5




**CADUS
      CORPORATION**


**Condensed
      Consolidated Statements of Cash Flows**





Three
                Months Ended
              March
                31,2007
            
            2006(Unaudited)
            
            (Unaudited)Cash
                flows from operating activities:Net
                (loss) income
            
            
            ($
                558,469
            )
            $
            100,811Adjustments
                to reconcile net (loss) income to net cash provided by operating
                activities:Amortization
                of patent costs
            
            
            21,608
            
            
            21,608(Income)
                of equity in other ventures
            
            
            (3,221
            )
            
            (2,369
            )Loss
                on write down of marketable securities
            
            
            668,246
            
            
            -Changes
                in assets and liabilities:(Increase)
                in prepaid and other current assets
            
            
            (16,200
            )
            
            (13,794
            )Increase
                in accrued expenses and other current liabilities
            
            
            85,885
            
            
            70,769Net
                cash provided by operating activities
            
            
            197,849
            
            
            177,025Net
                increase in cash and cash equivalents
            
            
            197,849
            
            
            177,025Cash
                and cash equivalents - beginning of period
            
            
            24,602,202
            
            
            24,044,619Cash
                and cash equivalents - end of period
            
            $
            24,800,051
            
            $
            24,221,644




See
      accompanying notes to condensed consolidated financial statements.




6


**CADUS
        CORPORATION**
 **Notes
        to Condensed Consolidated Financial Statements**


Note
      -
      1  **Organization
      and Basis of Preparation**





The
      information presented as of March 31, 2007 and for the three-month period then
      ended, is unaudited, but includes all adjustments (consisting only of normal
      recurring accruals) that the Company's management believes to be necessary
      for
      the fair presentation of results for the periods presented. Certain information
      and footnote disclosures normally included in financial statements prepared
      in
      accordance with accounting principles generally accepted in the United States
      of
      America have been omitted pursuant to the requirements of the Securities and
      Exchange Commission, although the Company believes that the disclosures included
      in these financial statements are adequate to make the information not
      misleading. The December 31, 2006 condensed consolidated balance sheet was
      derived from audited consolidated financial statements. These financial
      statements should be read in conjunction with the Company's annual report on
      Form 10-K for the year ended December 31, 2006.





The
      consolidated financial statements include the accounts of the Company and its
      wholly owned subsidiary, Cadus Technologies, Inc. All intercompany balances
      and
      transactions have been eliminated in consolidation.




The
      results of operations for the three-month period ended March 31, 2007 are not
      necessarily indicative of the results to be expected for the year ending
      December 31, 2007.





Note
      -
      2  **Net
      (Loss) Income Per Share**




For
      the
      three-month periods ended March 31, 2007 and 2006 basic net (loss) income per
      share is computed by dividing the net (loss) income by the weighted average
      number of common shares outstanding. Diluted earnings per share for the three
      months ended March 31, 2007 and 2006 was the same as basic earnings per share
      as
      all of the Company’s outstanding options’ and warrants’ exercise prices were
      greater than the average market price of the common shares. For this reason,
      for
      the three months ended March 31, 2007 and 2006, respectively, 2,500 and 57,167
      options and warrants were excluded from the calculation of diluted earnings
      per
      share.





Note
      -
      3  **Licensing
      Agreements**





In
      February 2000, Cadus licensed to OSI Pharmaceuticals, Inc. (“OSI”), on a
      non-exclusive basis, its yeast-based drug discovery technologies, including
      various reagents and its library of over 30,000 yeast strains, and its
      bioinformatics software. OSI paid to Cadus a license fee of $100,000 and an
      access fee of $600,000 and in December 2000 a supplemental license fee of
      $250,000. OSI is also obligated to pay an annual maintenance fee of $100,000
      until the earlier of 2010 or the termination of the license. OSI may terminate
      the license at any time on 30 days prior written notice. During the three-month
      period ended March 31, 2007 and 2006, the Company recognized $100,000 of license
      revenue related to this agreement.





Note
      -
      4  **Investment
      in Marketable Securities**





The
      Company had an equity interest in Axiom Biotechnologies, Inc. ("Axiom"). Due
      to
      Axiom's operating losses, the Company's investment was written down to $0 at
      December 31, 2001. On August 30, 2002, Axiom entered into a merger agreement
      with a wholly-owned subsidiary of Sequenom, Inc., which is publicly traded
      on
      the Nasdaq National Market. In connection with the merger, the Company received
      402,939 common shares of Sequenom, Inc. in exchange for its shares in Axiom
      after forfeiting 38,507 shares pursuant to the indemnification provisions of
      the
      merger agreement. On June 1, 2006, Sequenom, Inc. effected a one-for-three
      reverse stock split and the Company owned 134,313 common shares of Sequenom,
      Inc.




7


**CADUS
        CORPORATION**
 **Notes
        to Condensed Consolidated Financial
        Statements**


Pursuant
      to the provisions of Statement of Financial Accounting Standards No. 115, *"Accounting
      for Certain Debt and Equity Securities,"* management deemed its investment in Sequenom, Inc. to be available for sale
      and
      reported its investment at fair value with net unrealized gains or losses
      reported in accumulated other comprehensive (loss) income within stockholders'
      equity. At March 31, 2007, the investment was written down to $468,132,
      resulting in a loss of $668,246.





Note
      -
      5  **Accounting
      for Impairment of Long-Lived Assets**





Statement
      of Financial Accounting Standards No. 144, “ *Accounting
      for the Impairment or Disposal of Long-Lived Assets* ”
(“SFAS
      144"), addresses financial accounting and reporting for the impairment or
      disposal of long-lived assets. The Company’s long-lived assets (principally
      capitalized patent costs) are required to be measured at the lower of carrying
      amount or fair value, less cost to sell, whether reported in continuing
      operations or discontinued operations. Intangibles with determinable lives
      and
      other long-lived assets are reviewed for impairment whenever events or changes
      in circumstances indicate that the carrying value of an asset may not be
      recoverable. The Company’s judgments regarding the existence of impairment
      indicators are based on historical and projected future operating results,
      changes in the Company’s overall business strategy, and market and economic
      trends. In the future, events could cause the Company to conclude that
      impairment indicators exist and that certain intangibles with determinable
      lives
      and other long-lived assets are impaired which may result in an adverse impact
      on the Company’s financial condition and results of operations. The provisions
      of SFAS No. 144 did not have an impact on the Company’s financial statements as
      of and for the three months ended March 31, 2007.





Note
      -
      6  **Recently
      Issued Accounting Pronouncements**





In
      December 2004, the Financial Accounting Standards Board (“FASB”) issued
      Statement of Financial Accounting Standards (“SFAS”) No. 123R *“Share
      Based Payment.”* This
      statement is a revision to SFAS No. 123, supersedes Accounting Principles Board
      (“APB”) No. 25, *“Accounting
      for Stock Issued to Employees,”* and
      amends SFAS No. 95, *“Statement
      of Cash Flows.”* This
      statement requires the Company to expense the cost of employee services received
      in exchange for an award of equity instruments. This statement also provides
      guidance on valuing and expensing these awards, as well as disclosure
      requirements, and became effective during the reporting period ended March
      31,
      2006.





On
      March
      20, 2006, the Company adopted the modified prospective method in accounting
      for
      share-based payment in which compensation cost is recognized beginning with
      the
      effective date (a) based on the requirements of SFAS No. 123R for all
      share-based payments granted after the effective date and (b) based on the
      requirements of SFAS No. 123 for all awards granted to employees prior to the
      effective date of SFAS No. 123R that remain unvested on the effective date.
      Previously, as permitted by SFAS No. 123, the Company accounted for share-based
      payments to employees using the APB No. 25 intrinsic value method and recognized
      no compensation cost for employee stock options. The impact of the adoption
      of
      SFAS No. 123R cannot be predicted at this time because it will depend on levels
      of share-based payments granted in the future. However, valuation of employee
      stock options under SFAS No. 123R is similar to SFAS No. 123, with some
      exceptions. The adoption of SFAS No. 123R's fair value method may have an impact
      on the Company's results of operations, although it will have no impact on
      its
      overall financial position.




8


**CADUS
        CORPORATION**
 **Notes
        to Condensed Consolidated Financial
        Statements**


Pro
      forma
      net income and basic and diluted earnings per share as if the fair-value-based
      method had been applied to all awards is not required since all options were
      vested prior to all periods presented.





Options
      granted under the Company’s 1996 Incentive Plan expire ten years from date of
      grant. Under the 1996 Incentive Plan, there are currently outstanding options
      to
      purchase 2,500 shares of common stock at an exercise price of $6.38 per share
      The following table summarizes stock option information for such grants as
      of
      March 31, 2007 :





Options
                Outstanding
            
            Options
                ExercisableRange
                ofExercise
                Prices
            
            NumberOutstanding
            
            Weighted
                Average RemainingContractual
                Life
            
            Weighted
                AverageExercise
                Price
            
            NumberExercisable
            
            Weighted
                AverageExercise
                Price$6.38
            
            
            2,500
            
            
            0.68
            
            $
            6.38
            
            
            2,500
            
            $
            6.38





Note
      -
      7  **Comprehensive
      Income**





The
      Company classifies its investment in marketable securities as
      available-for-sale.





Unrealized
                gains and losses on available-for-sale securities are reported in
                accumulated other comprehensive (loss) income, a component of
                stockholders’ equity. There was no comprehensive income for the three
                months ended March 31, 2007.





Other
                comprehensive income for the three months ended March 31, 2006
                was:




Net
                  income
              
              $
              100,811Accumulated
                  other comprehensive income
              
              
              36,264Comprehensive
                  income
              
              $
              137,075





9




ITEM
                2.
            **MANAGEMENT'S
                DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF
                OPERATIONS**





**Overview**





The
      Company was incorporated in 1992 and until July 30, 1999, devoted substantially
      all of its resources to the development and application of novel yeast-based
      and
      other drug discovery technologies. On July 30, 1999, the Company sold its drug
      discovery assets and ceased its internal drug discovery operations and research
      efforts for collaborative partners.





At
      March
      31, 2007, the Company had an accumulated deficit of approximately $33.7 million.
      The Company’s losses have resulted principally from costs incurred in connection
      with its research and development activities and from general and administrative
      costs associated with the Company’s operations. These costs have exceeded the
      Company’s revenues and interest income. As a result of the sale of its drug
      discovery assets and the cessation of its internal drug discovery operations
      and
      research efforts for collaborative partners, the Company ceased to have research
      funding revenues and substantially reduced its operating expenses. The Company
      expects to generate revenues in the future only if it is able to license its
      technologies.





**Results
      of Operations**





*Three
      Months Ended March 31, 2007 and March 31, 2006*





*Revenues*





Revenues
      for the three months ended March 31, 2007 and 2006 were $100,000, which is
      the
      annual maintenance fee from OSI.





*Costs
      and Expenses*





General
      and administrative expenses increased to $314,091 for the three months ended
      March 31, 2007 from $261,202 for the same period in 2006. Professional fees
      increased by $27,661 and, because of the timing of payment in 2007 in the first
      quarter and in 2006 in the second quarter, license fee increased by $25,000.
      There were net increases in other expenses of $228.





For
      the
      three months ended March 31, 2007 the Company recognized income of $3,221 in
      its
      investment in Laurel Partners Limited Partnership. The income for the same
      period in 2006 was $2,369.





*Interest
      Income*





Interest
      income for the three months ended March 31, 2007 was $320,647 compared to
      interest income of $259,644 for the same period in 2006. This increase is
      attributable primarily to higher interest rates earned on invested
      funds.




*Net
      (Loss) Income*





Net
      loss
      for the three months ended March 31, 2007 was $558,469 compared to net income
      of
      $100,811 for the same period in 2006. This decrease can be attributed to a
      $668,246 write down of marketable securities and to the increase of expenses
      of
      $52,889, offset by an increase in interest income of $61,003.




10




*Liquidity
      and Capital Resources*





At
      March
      31, 2007 the Company held cash and cash equivalents of $24.8 million. The
      Company's working capital at March 31, 2007 was $25.1 million.





The
      Company believes that its existing capital resources, together with interest
      income, will be sufficient to support its operations through the end of 2008.
      This forecast of the period of time through which the Company's financial
      resources will be adequate to support its operations is a forward-looking
      statement that may not prove accurate and, as such, actual results may vary.
      The
      Company's capital requirements may vary as a result of a number of factors,
      including the transactions, if any, arising from the Company's efforts to
      acquire or invest in companies and income-producing assets and the expenses
      of
      pursuing such transactions.





Item
                3.
            **QUANTITATIVE
                AND QUALITATIVE DISCLOSURES ABOUT MARKET
                RISK**





The
      Company's earnings and cash flows are subject to fluctuations due to changes
      in
      interest rates primarily from its investment of available cash balances in
      money
      market funds with portfolios of investment grade corporate and U.S. government
      securities. The Company does not believe it is materially exposed to changes
      in
      interest rates. Under its current policies the Company does not use interest
      rate derivative instruments to manage exposure to interest rate
      changes.





Item
      4.  **CONTROLS
      AND PROCEDURES**





Based
      on
      the evaluation of the Company’s disclosure controls and procedures conducted as
      of the end of the period covered by this report on Form 10-Q, the Company’s
      President and Chief Executive Officer, who also performs the functions of a
      principal financial officer, concluded that the Company’s disclosure controls
      and procedures (as defined in Rules 13a-15(e) and 15d-15(e) promulgated under
      the Securities Exchange Act of 1934) are effective. In addition, there has
      been
      no change in the Company’s internal control over financial reporting (as defined
      in Rule 13a-15(f) and 15d-15(f) under the Securities Exchange Act of 1934)
      that
      occurred during the period covered by this report on Form 10-Q that has
      materially affected, or is reasonably likely to materially affect, the Company’s
      internal control over financial reporting. It should be noted that any system
      of
      controls, however well designed and operated, can provide only reasonable
      assurance, and not absolute assurance, that the objectives of the system are
      met. In addition, the design of any control system is based in part upon certain
      assumptions about the likelihood of future events. Because of these and other
      inherent limitations of control systems, there can be no assurance that any
      design will succeed in achieving its stated goals under all potential future
      conditions, regardless of how remote.





**PART
      II - OTHER INFORMATION**





ITEM
      1.  LEGAL
      PROCEEDINGS .





None.





ITEM
      1A.  RISK
      FACTORS .




11





There
      were no material changes from the risk factors previously disclosed in our
      Annual Report on Form 10-K for the period ended December 31, 2006 as filed
      with
      the Securities and Exchange Commission on March 30, 2007.





ITEM
      2.  UNREGISTERED
      SALES OF EQUITY SECURITIES AND USE OF PROCEEDS.





None.





ITEM
      3.  DEFAULTS
      UPON SENIOR SECURITIES.





None.





ITEM
      4.  SUBMISSION
      OF MATTERS TO A VOTE OF SECURITY HOLDERS.








On
      January 10, 2007, the Company held its annual meeting of stockholders in New
      York, New York. The holders of 12,962,170 shares of Common Stock were present
      or
      represented by proxy and, accordingly, a quorum was present. The following
      matter was voted upon and received the votes set forth below:





All
      of
      the following persons nominated were elected to serve as directors and received
      the number of votes set opposite their respective names:


Votes
                  For
              
              Votes WithheldJames
                  R. Broach
              
              
              12,417,648
              
              
              544,522Russell
                  D. Glass
              
              
              12,407,048
              
              
              555,122Carl
                  C. Icahn
              
              
              12,429,765
              
              
              532,405Peter
                  S. Liebert
              
              
              12,429,765
              
              
              532,405Jack
                  G. Wasserman
              
              
              12,429,765
              
              
              532,405


ITEM
      5.  OTHER
      INFORMATION .





None.





ITEM
      6.  EXHIBITS .





The
      Exhibits listed in the Exhibit Index are included in this quarterly report
      on
      Form 10-Q.




12




**SIGNATURES**








Pursuant
      to the requirements of the Securities Exchange Act of 1934, the registrant
      has
      duly caused this report to be signed on its behalf by the undersigned thereunto
      duly authorized.




**CADUS
                CORPORATION**
                **(Registrant)**Dated:May
              11, 2007
            By:
            /s/
              David BlitzDavid
                BlitzPresident
                and
                Chief Executive Officer (Authorized Officer
              and
                Principal Financial Officer)


13




**EXHIBIT
      INDEX**





The
      following exhibits are filed as part of this Quarterly Report on Form
      10-Q:




Exhibit
                No.
              
              Description31
              
              Certifications32
              
              Certification
                  Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section
                  906 of
                  the Sarbanes-Oxley Act of 2002


14